Back to News
Market Impact: 0.4
Dyne's DYNE-101 Shows One-Year Functional Improvement In DM1 Study
Source: Nasdaq
Healthcare & Biotech
Dyne Therapeutics reported additional one-year Phase 1/2 ACHIEVE trial data showing that zeleciment basivarsen (DYNE-101) improved multiple functional measures in patients with myotonic dystrophy type 1. The positive durability data support continued clinical development of the DM1 therapy and could be material for Dyne shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
DYN0.78
More News
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Why is Toho stock volatile today?
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Some Oura IPO Investors Were Said to Push Back Citing Valuation